Double-blind crossover clinical and pharmacokinetic comparison of oral morphine syrup and sustained release morphine sulfate capsules in patients with cancer-related pain

Clinical Drug Investigation

Volumn 14, Issue SUPPL. 1, 1997, Pages 22-27

  Gillette, Jean François ^a,i   Ferme, Christophe ^b   Moisy, Nancy ^c   Mignot, Laurent ^d   Schach, Roger ^e   Vignaux, Jean René ^f   Besner, Jean G ^g   Caille, Gilles ^g   Belpomme, Dominique ^h  

^a CENTRE RENÉ HUGUENIN   (France)

^b CMC de Bligny   (France)

^c BICHAT HOSPITAL   (France)

^d FOCH HOSPITAL   (France)

^e CENTRE PAUL STRAUSS   (France)

^f INSTITUT CLAUDIUS REGAUD   (France)

^g UNIVERSITÉ DE MONTRÉAL   (Canada)

^h ARTAC   (France)

ⁱ Serv d'Anesthesie reanimation   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; MORPHINE SULFATE; OPIATE;

ADULT; ADVANCED CANCER; AGED; AGITATION; ANALGESIA; AREA UNDER THE CURVE; BIOEQUIVALENCE; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; EUPHORIA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; NIGHTMARE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE; URINE RETENTION; VERTIGO; XEROSTOMIA;

EID: 0030806659     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199700141-00006     Document Type: Conference Paper

References (11)

1. Melzack R, Ofiesh JH, Mount BM. The Brompton mixture: effects on pain in cancer patients. Can Med Assoc J 1976; 115: 125-9
2. Hanks GW, Twycross RG, Bliss JM. Controlled release morphine tablets: a double blind trial in patients with advanced cancer. Anaesthesia 1987; 42: 840-4
3. Besner JG, Krishnamurthy TN, Horodniak J. High performance liquid chromatography of morphine in human plasma with coulometric detector [poster presentation]. International Symposium on Drug Analysis; 1985 Sep: Ottawa
4. Warfield CA. Guidelines for routine use of controlled release oral morphine sulfate tablets. Semin Oncol 1993; 20 (2 Suppl. 1): 36-47
5. Cherny NI. Opioid analgesics: comparative features and prescribing guidelines. Drugs 1996; 51: 713-37
6. Hoskin PJ, Poulain P. Hanks GW. Controlled-release morphine in cancer patients. Anaesthesia 1989; 44: 897-901
7. Thirlwell MP, Sloan PA, Maroun JA, et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled release morphine tablets in cancer patients. Cancer 1989; 63 (11 Suppl.): 2275-83
8. Donnadieu S, Hernot M, Suard L. Oral administration of sustained release morphine sulfate granules in patients with pain and dysphagia associated with cancer. Clin Drug Invest 1997; 14 Suppl. 1: 43-52
9. Khojasteh A, Evans W, Reynolds RD, et al. Controlled-release oral morphine sulfate in the treatment of cancer pain with pharmacokinetic correlation. J Clin Oncol 1987; 5: 956-61
10. Säwe J, Dahlström B, Rane A. Steady state kinetics and analgesic effect of oral morphine in cancer patients. Eur J Clin Oncol 1983; 24: 537-42
11. Bruera E, Fainsinger R, Spachinsky K, et al. Steady state pharmacokinetic evaluation of a novel controlled release morphine suppository and subcutaneous morphine in cancer pain. J Clin Pharmacol 1995; 35: 666-72